PhD Tanja Jesenko

PhD Tanja Jesenko
no.: 33227 source: ARIS

researcher – active in research organisation
  tjesenkoat signonko-i.si
Edit
Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   
Bibliography Representative bibliographic units | Personal | COBISS+
source: COBISS
source: SICRIS
Evaluation (metodology)
Evaluation of bibliographic research performance indicators according to ARIS methodology
source: COBISS
source: ARIS
Points
495.12
A''
0
A'
312.69
A1/2
384.1
CI10
567
CImax
66
h10
13
A1
1.79
A3
5
Data for the last 5 years (citations for the last 10 years) on October 15, 2025; Data for score A3 calculation refer to period 2020-2024 (2019, 2020, 2021, 2022, 2023)
Data for ARIS tenders ( 23.05.2022 – Target research programmes, archive )
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Database Linked records Citations Pure citations Average pure citations
WoS 53  738  469  8.85 
Scopus 48  862  567  11.81 
Mentoring junior researchers
source: ARIS
no. Name and surname Type Period Code
1 PhD Živa Pišljar   Bologna doctoral studies  10/1/2020 - 9/30/2024  54718 
Education
source: ARIS
Level of education Professional title Study subject Faculty Year
      SI Univeristy of Ljubljana, Faculty of Chemistry and Chemical Technology 2010 
Doctoral degree  Ph. D.   Biomedicine  SI University of Ljubljana, Faculty of Medicine 2014 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Employments
source: ARIS
Type of employment Research org. Research group Date of employment Position Role Title
Full time employment (100%, RD:100%)  Institute of Oncology Ljubljana  Department of research  11/1/2010    Researcher   
Research projects Legend
source: ARIS
no. Code Title Period Head
1. J3-60068  Circulating tumor cell translational research platform.   1/1/2025 - 12/31/2027  PhD Tanja Jesenko   2,923 
2. J1-60017  Perfusion, Edema, and Necrosis Evaluation using OCT for Tumor Outcome Measures   1/1/2025 - 12/31/2027  PhD Jošt Stergar   2,743 
3. J3-50108  DEBIO 1143 has a potential to increase effectiveness of electrochemotherapy and radiotherapy in HPV positive and HPV negative Head and Neck Cancers   10/1/2023 - 9/30/2026  PhD Katarina Žnidar   2,397 
4. J4-50150  Erythrocyte membrane-based nanocarriers for gene silencing cancer therapy   10/1/2023 - 9/30/2026  PhD Nina Kostevšek   4,220 
5. L3-50111  Gene immuno-therapy of solid tumors based on mRNA encoding interleukin-12: So-rIL   10/1/2023 - 9/30/2026  PhD Maja Čemažar   3,048 
6. J3-50110  Intratumoral mRNA electrotransfer: establishment and preclinical proof of concept   10/1/2023 - 9/30/2026  PhD Katja Uršič Valentinuzzi   3,367 
7. J2-50068  Safety and efficacy of high frequency electrochemotherapy - clinical device development   10/1/2023 - 9/30/2026  PhD Matej Reberšek   3,729 
8. J7-4635  MitoCan - Preclinical development of new Mitochondrial ion channel inhibitors for Cancer therapy   10/1/2022 - 9/30/2026  PhD Lucija Peterlin Mašič   6,640 
9. L7-4491  Development of integrated multi-channel artificial nose for detection of cancer   10/1/2022 - 9/30/2025  PhD Igor Muševič   5,928 
10. J3-3083  Vascularization and vascular effects as predictive factors for local ablative techniques   10/1/2021 - 9/30/2025  PhD Gregor Serša   7,319 
11. J3-2528  Immuno gene electrotransfer of IL-12 and IL-2 in immunologically cold/hot tumors   9/1/2020 - 8/31/2023  PhD Maja Čemažar   3,424 
12. J3-2529  Role of endothelium in tumor response to radiotherapy   9/1/2020 - 8/31/2023  PhD Boštjan Markelc   3,723 
13. J7-2594  The amniotic membrane as a novel multimodal therapy for bacterial cystitis and bladder cancer: unravelling its antimicrobial, immunomodulatory and anticancer activity   9/1/2020 - 8/31/2023  PhD Mateja Erdani Kreft   5,600 
14. Z3-8204  Involvement of cytosolic DNA sensors in irradiation induced bystander and abscopal effect   4/1/2018 - 3/31/2020  PhD Tanja Jesenko   202 
15. J1-6730  Razvoj novih celičnih linij človeških jeter za raziskave genotoksičnosti in karcinogenosti: novo upanje za človekovo zdravje in zaščito laboratorijskih živali (Slovene)   11/1/2014 - 10/31/2017  PhD Metka Filipič   4,374 
16. J3-6793  Novi pristopi radiosenzibilizacije tumorjev z gensko terapijo (Slovene)   7/1/2014 - 6/30/2017  PhD Gregor Serša   5,483 
17. J3-6796  Translacijska onkologija: razvoj in validacija imunsko genske terapije z interleukinom-12 v kombinaciji s kirurgijo pri oralnih in kožnih tumorjih psov (Slovene)   7/1/2014 - 6/30/2017  PhD Maja Čemažar   5,190 
18. J3-5505  Elektrokemoterapija globoko ležečih tumorjev (Slovene)   8/1/2013 - 7/31/2016  PhD Gregor Serša   4,555 
19. J3-4259  Priprava in validacija terapevtskih plazmidov brez selekcijskega gena za antibiotično rezistenco za gensko terapijo raka z inducibilnimi in tkivno specifičnimi promotorji (Slovene)   7/1/2011 - 6/30/2014  PhD Maja Čemažar   6,296 
20. L2-4105  Razvoj programa za numerično modeliranje elektroporacije in vivo ter njegova validacija? in silico elektroporacija (Slovene)   7/1/2011 - 6/30/2014  PhD Damijan Miklavčič   5,159 
ARIS research and infrastructure programmes Legend
source: ARIS
no. Code Title Period Head
1. P3-0003  Development and evaluation of new approaches to cancer treatment   1/1/2022 - 12/31/2027 PhD Gregor Serša   4,393 
2. P3-0003  Development and evaluation of new approaches to cancer treatment   1/1/2015 - 12/31/2021 PhD Gregor Serša   3,528 
3. P3-0003  Development and evaluation of new approaches to cancer treatment   1/1/2009 - 12/31/2014 PhD Gregor Serša   4,296 
Confirmation required
Views history
Favourite